Table 1. Relationship between the FSCN1 and MMP14 expression and clinicopathological features.
|
FSCN1 expression |
MMP14 expression |
|||||
|---|---|---|---|---|---|---|
| − (n=58) | + (n=82) | P-value | − (n=72) | + (n=68) | P-value | |
|
Age, years | ||||||
| <65 (n=81) | 37 | 44 | 42 | 39 | ||
| ⩾65 (n=59) |
21 |
38 |
0.23 |
30 |
29 |
0.91 |
|
Gender | ||||||
| Male (n=121) | 50 | 7 | 63 | 57 | ||
| Female (n=20) |
8 |
12 |
0.89 |
9 |
11 |
0.70 |
|
Tumour depth | ||||||
| Tis, T1 (n=60) | 36 | 24 | 38 | 22 | ||
| T2, T3, T4 (n=80) |
22 |
58 |
0.00011 |
34 |
46 |
0.015 |
|
Regional lymph nodes | ||||||
| N0 (n=66) | 33 | 33 | 43 | 23 | ||
| N1 (n=74) |
25 |
49 |
0.052 |
29 |
45 |
0.0022 |
|
Stage | ||||||
| stage0, I (n=35) | 24 | 11 | 27 | 8 | ||
| stageII, III, IV (n=105) |
34 |
71 |
0.00017 |
45 |
60 |
0.00090 |
|
Lymphatic invasion | ||||||
| ly0 (n=51) | 25 | 26 | 33 | 18 | ||
| ly1, 2, 3 (n=89) |
33 |
56 |
0.17 |
39 |
50 |
0.017 |
|
Vacular invasion | ||||||
| v0 (n=57) | 28 | 29 | 36 | 21 | ||
| v1, 2, 3 (n=83) |
30 |
53 |
0.13 |
36 |
47 |
0.021 |
|
Histology | ||||||
| Well, mod (n=111) | 45 | 66 | 59 | 52 | ||
| Poor (n=29) |
13 |
16 |
0.68 |
13 |
16 |
0.42 |
|
Recurrence | ||||||
| Recurrence (n=56) | 14 | 42 | 16 | 40 | ||
| No recurence (n=84) | 44 | 40 | 0.0013 | 56 | 28 | 0.000010 |
Abbreviation: MMP14=matrix metalloproteinase 14.